Socioeconomic Factors do not but GH treatment does affect mortality in adult-onset growth hormone deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4141-4148

  Stochholm, Kirstine ^a   Berglund, Agnethe ^a   Juul, Svend ^b   Gravholt, Claus Højbjerg ^a   Christiansen, Jens S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; COHABITATION; CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; DELINQUENCY; DENMARK; EDUCATIONAL STATUS; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; INCIDENCE; INCOME; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PARENTHOOD; PRIORITY JOURNAL; RETIREMENT; SOCIAL STATUS; EPIDEMIOLOGY; HYPOPITUITARISM; MIDDLE AGED; REGISTER; RISK FACTOR; SOCIAL CLASS; SOCIOECONOMICS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; DENMARK; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INCOME; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SOCIAL CLASS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84909989406     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1814     Document Type: Article

References (20)

1. Akinci A, Kanaka C, Eble A, Akar N, Vidinlisan S, Mullis PE. Isolated growth hormone (GH) deficiency type IA associated with a 45-kilobase gene deletion within the human GH gene cluster. J Clin Endocrinol Metab. 1992; 75(2): 437-441.
2. Dean H, McTaggart T, Fish D, Friesen H. The educational, vocational, and marital status of growth hormone-deficient adults treated with growth hormone during childhood. Am J Dis Child. 1985; 139(11): 1105-1110.
3. Galatzer A, Aran O, Beit-Halachmi N, et al. The impact of long-term therapy by a multidisciplinary team on the education, occupation and marital status of growth hormone deficient patients after termination of therapy. Clin Endocrinol (Oxf). 1987; 27(2): 191-196.
4. Sandberg D, Gillivray MH, Clopper RR, Fung C, LeRoux L, Alliger DE. Quality of life among formerly treated childhood-onset growth hormone-deficient adults: a comparison with unaffected siblings. J Clin Endocrinol Metab. 1998; 83(4): 1134-1142.
5. Mukherjee A, Tolhurst-Cleaver S, Ryder WD, Smethurst L, Shalet SM. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy. J Clin Endocrinol Metab. 2005; 90(3): 1542-1549.
6. Stochholm K, Juul S, Christiansen J, Gravholt C. Mortality and socio-economic status in adults with childhood onset growth hormone deficiency is highly dependent on the primary cause of GHD. Eur J Endocrinol. 2012; 167(5): 663-670.
7. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012; 97(2): 416-425.
8. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002; 360(9329): 273-277.
9. Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab. 2000; 13(suppl 2): 1035-1044.
10. Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012; 97(2): E213-E217.
11. Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and causespecific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012; 166(6): 1069-1077.
12. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004; 89(7): 3306-3312.
13. van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011; 96(10): 3151-3159.
14. Stochholm K, Gravholt C, Laursen T, et al. Incidence of GH deficiency - A nationwide study. Eur J Endocrinol. 2006; 155(1): 61-71.
15. Stochholm K, Gravholt C, Laursen T, et al. Mortality in growth hormone deficiency - A nationwide study. Eur J Endocrinol. 2007; 157: 9-18.
16. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990; 336(8710): 285-288.
17. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997; 46(1): 75-81.
18. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996; 81(3): 1169-1172.
19. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001; 357(9254): 425-431.
20. Bates AS, Bullivant B, Sheppard MC, Stewart PM. Life expectancy following surgery for pituitary tumours. Clin Endocrinol (Oxf). 1999; 50(1999): 315-319.